LONDON, July 31, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Tuesday, July 30, 2013, shares in healthcare companies ended on a mixed note, tracking the broader market. The major movers in the sector included Celgene Corporation (NASDAQ: CELG), Edwards Lifesciences Corp. (NYSE: EW), Forest Laboratories Inc. (NYSE: FRX), and Peregrine Pharmaceuticals (NASDAQ: PPHM). AAAResearchReports.com has released full comprehensive research on CELG, EW, FRX, and PPHM. These free technical analyses can be downloaded by signing up at:
Shares in Celgene Corporation moved higher on Tuesday, extending their gains from previous trading sessions. The company's shares hit a 52-week high of $146.22 before finishing the day 1.90% higher at $145.37. A total of 2.87 million shares were traded which is above the daily average volume of 2.72 million. The stock has gained 3.36% in the last three trading sessions as compared to a loss of 0.25% in the S&P 500. Moreover, the stock is currently trading above its 50-day and 200-day moving averages. Download free report on CELG upon registration at:
Edwards Lifesciences Corp.'s stock edged lower on Tuesday, ending the session at $70.51, down 0.70% from its previous closing price. The company's shares fluctuated between $70.33 and $71.44. A total of 0.81 million shares were traded which is below the daily average volume of 1.12 million. The company's shares have gained 4.93% in the last one month and 10.53% in the last three months as compared to a gain of 4.96% and 5.53% in the S&P 500 during the respective periods. EW technical report can be accessed for free by signing up at:
Shares in Forest Laboratories Inc. edged higher on Tuesday, reversing some of their recent losses. The company's shares oscillated between $43.58 and $44.20 before finishing the day 0.44% higher at $43.77. A total of 0.84 million shares were traded which is below the daily average volume of 1.84 million. Forest Laboratories' shares have fallen by 0.50% in the last three trading sessions, thus underperforming the S&P 500. Despite Tuesday's pullback, the stock is still trading around its 52-week high of $44.87. The free report on FRX can be downloaded by signing up now at:
Peregrine Pharmaceuticals struggled for direction on Tuesday before finishing the day flat. The company's shares ended the day at $1.43 after oscillating between $1.43 and $1.47. A total of 1.34 million shares were traded which is below the daily average volume of 2.40 million. Peregrine Pharmaceuticals' shares have gained 10.85% in the last one month, hence outperforming the S&P 500. A free report on PPHM can be accessed by registering at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE AAA Research Reports